Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (20914)	5/16/1998 6:14:00 AM
From: Henry Niman	Respond to of 32384

bob, Panretin reacts with a six known retinoic acid receptors (3 RARs and 3 RXRs). Retinoids (which bind to RARs) have been known to cause some of the side effects described in the abstract (headaches and elevated triglycerides). Thus the RAR activity may be responsible for the side effects. It's not clear from the synopsis exactly how ill these patients were. I believe that this is the study sponsored by the government (AIDS Malignancy Consortium), but don't know exactly who was enrolled.

To: bob zagorin who wrote (20914)	5/16/1998 7:30:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

ASCO begins today (see asco.org ) and chemoprevention will be a hot topic. LLY will show striking data for Evista (Raloxifene) and the press should be all over this one. Results of combining Panretin with Tamoxifen to treat breast cancer in humans might generate some coverage. Targretin and Panretin have been shown to prevent breast cancer in rats and both have been shown to synergize with Tamoxifen and Evista. Lately there has also been a good deal of coverage on Tamoxifen being under prescribed for treating breast cancer.